← Back to Search

Other

ANG-3070 for Proteinuria

Phase 2
Waitlist Available
Research Sponsored by Angion Biomedica Corp
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial is testing ANG-3070, a new drug, in people with a kidney disease that causes protein loss in urine. The goal is to see if it can improve kidney function and reduce the amount of protein lost.

Eligible Conditions
  • Proteinuria
  • Glomerulonephritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: 400 mg QDExperimental Treatment1 Intervention
400 mg of ANG-3070 will be taken once daily for 12 weeks
Group II: 300 mg BIDExperimental Treatment1 Intervention
300 mg of ANG-3070 will be taken twice a day for 12 weeks.
Group III: 200 mg QDExperimental Treatment1 Intervention
200 mg of ANG-3070 will be taken once daily for 12 weeks.
Group IV: PlaceboPlacebo Group1 Intervention
Placebo capsules will be taken once or twice daily for 12 weeks.

Find a Location

Who is running the clinical trial?

Angion Biomedica CorpLead Sponsor
11 Previous Clinical Trials
862 Total Patients Enrolled
John Neylan, MDStudy DirectorAngion Biomedica
3 Previous Clinical Trials
628 Total Patients Enrolled
~27 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top